Shares in Novo Nordisk (NYSE:NVO) were up 2% this morning after the European Medicines Agency’s Committee for Medicinal Products for Human Use backed the company’s application for a label update to its Tresiba insulin injection.
The company submitted an application in November to add data from 2 studies to the medication’s label. The final ruling is expected to come from the committee in 60 days.
Get the full story at our sister site, Drug Delivery Business News.